Global Hematuria Treatment Market Overview
Hematuria Treatment Market Size was valued at USD 1.1 Billion in 2022. The Hematuria Treatment market industry is projected to grow from USD 1.13 Billion in 2023 to USD 1.40 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.70% during the forecast period (2023 - 2032). Rising chronic disease incidence is the key market drivers accelerating market expansion.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
In November 2023, EndoChoice Holdings, Inc. announced that it had completed the medical trials that have shown or demonstrated the efficacy of its endoscopic technology for diagnosing and treating hematuria.
KARL STORZ SE & Co. KG launched the newest ureteroscope constructed in October 2023 to enhance diagnostics along with interventions within hematuria and additional urogenital diseases.
Richard Wolf GmbH introduced a flexible ureteroscope having or consisting of new imaging capabilities improving the treatment and therapy of hematuria along with other urogenital pathologies in July 2022.
The newest cystoscopy system from Boston Scientific Corporation approved by FDA in May 2022, is aimed at increasing the visibility during procedures of hematuria management problems, including other urinary pathway malformations.
Farxiga (dapagliflozin) oral tablets were approved by the FDA in April 2021 for lowering kidney failure, cardiovascular mortality, renal function decline and heart stoppage hospitalization abnormalities among people or individuals having chronic kidney disease who are prone to the progression of their chronic renal disorder.
Astra Zeneca and Vax Equity announced their collaboration in September 2021 for the RNA therapeutics platform development and commercialization.
In February 2020, Exblifep by Da Volterra was launched to satisfy unmet needs for complex UTIs, a combination of enmetazobactam, a new extended-spectrum beta-lactamase inhibitor and cefepime which is dedicated to fourth-generation cephalosporin that had satisfied primary endpoints within this clinical research program.
FDA approved Recarbrio (imipenem-cilastatin-relebactam) in 2019 for treating patients with complex urinary tract infections (cUTI) and difficult intra-abdominal infections (cIAI).
Hematuria Treatment Market Trends
- Rising chronic disease incidence is driving the market growth
Market CAGR for hematuria treatment is being driven by the rising chronic disease incidence. Bleeding in the urine is referred to clinically as hemoturia. Humans produce urine, which is filtered by a kidney, which normally keeps blood out of the urine. Blood in the urine is a symptom of many different medical disorders, including kidney damage, cancer, enlarged prostate, bladder stones, kidney infections (pyelonephritis), and renal illness, and kidney disease, Urinary tract infections. Investigating the clinical aetiology of hematuria is crucial because, if addressed, it could develop into a potentially fatal illness. Despite the fact that blood in the urine is not usually an indication of sickness, it can be a serious indicator of a potential medical problem. Different antibiotics are suggested for treatment depending on which part of the tract is being addressed.
Additionally, the rising prevalence of chronic diseases has caused a significant increase in healthcare spending, which is a key factor in the market's revenue growth. The modernization of healthcare infrastructure is being funded in large part by the governments of various economies. Additionally, patients in industrialized economies are learning more about the hematuria treatments that are accessible. Oral medications are predicted to accelerate market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a very practical mode of administration, the category is anticipated to accelerate the market. The operations and the projected market growth that have been set for the forecast period are likely to be hampered by the arrival of numerous decrease in the availability of medical experts to provide hematuria treatment. The ability for pharmaceutical companies to introduce novel medicines and potential pipeline products has been made possible by intensive research and development efforts, the advent of high-throughput screening (HTS) for drug development, and approval by the FDA for drugs. Furthermore, rising opportunities for related therapies are projected to offer significant potential opportunities for the players in the hematuria treatment market to increase their client bases, particularly in emerging nations.
For instance, overactive bladder symptoms are present in 70% to 80% of persons over the age of 80, according to the International Incontinence Society. People over the age of 35 are more likely to experience the symptoms of hematuria, which is more common as people become older. Thus, result in driving the Hematuria Treatment market revenue.
Hematuria Treatment Market Segment Insights
Hematuria Treatment Type Insights
The Hematuria Treatment market segmentation, based on type includes Gross or Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger's Hematuria. The microscopic hematuria segment dominated the market in the year 2022. The segment is dominating the market because more people are becoming hematuric with tiny blood in their urine. Microscopic hematuria is typically diagnosed during routine testing rather than after the patient experiences symptoms.
Hematuria Treatment Causes Insights
The Hematuria Treatment market segmentation, based on Causes, includes Kidney Stones, Urinary Tract Infections (UTI), Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation. The urinary tract infections (UTI) category generated the most income. The key factor boosting the market is the rise in UTI infections among women. The urinary system as a whole is affected by a urinary tract infection, including the kidneys, bladder, urethra, and other areas.
Hematuria Treatment Treatment Insights
The Hematuria Treatment market segmentation, based on Treatment, includes Drugs, Therapeutics, and Others. The drugs category generated the most income. Considering the illness, the amount of urine that is expelled from the body is increased by antibiotics and drugs, and the labor that the kidneys must do is lessened by blood pressure medications and dietary changes.
Hematuria Treatment End-Users Insights
The Hematuria Treatment market segmentation, based on End-Users, includes Hospitals, Clinics, Laboratories, Research Centers, and Others. The hospitals generated the most income. This is due to the fact that numerous pharmaceutical companies have used cutting-edge techniques and technologies to meet the needs and demands of the general public for the treatment of hematuria. Additionally, the use of antibiotics to treat urinary tract infections, shock wave therapy to treat bladder or kidney stones, and medications to shrink enlarge prostate glands are contributing to the rise of the hospital segment's market during the forecast period.
Figure1: Hematuria Treatment Market, by End-Users, 2022&2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Hematuria Treatment Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia Pacific Hematuria Treatment market area will be dominant, due to the expansion of healthcare facilities, the prevalence of generic manufacturers, the growth of government initiatives, and the emergence of specialized communities.
Further, the major countries studied in the market report are The US, Germany, Canada, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil.
Figure2: HEMATURIA TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Hematuria Treatment market accounts for the second-largest market share due to the desire for novel therapies, as well as other significant reasons including the enormous research being conducted in the area of treating urinary tract infections, the market participants have begun to expand internationally. Further, the German Hematuria Treatment market held the largest market share, and the UK Hematuria Treatment market was the European region's fastest-growing market.
The North America Hematuria Treatment Market is predicted to see the highest CAGR between 2023 and 2032. This is because of the early adoption of branded products, favorable healthcare reimbursement regulations, recent FDA permits, the vast number of drugs in development, the emphasis on reducing the overall number of unresolved hematuria cases, and the early treatment of hematuria. Moreover, China’s Hematuria Treatment market held the largest market share, and the Indian Hematuria Treatment market was the Asia-Pacific region's fastest-growing market.
Hematuria Treatment Key Market Players& Competitive Insights
Leading market players are paying a large sum of money on research and development in order to expand their product lines, which will help the Hematuria Treatment market, grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Hematuria Treatment industry must provide affordable options.
One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the Hematuria Treatment industry to benefit clients and increase the market sector. In recent years, the Hematuria Treatment industry has offered some of the most significant advantages to medicine. Major players in the Hematuria Treatment market, including AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company and others are making investments in research and development activities in an effort to boost market demand.
AstraZeneca plc is a worldwide pharmaceutical and biotechnology business with British and Swedish roots. Its headquarters are in Cambridge, England's Cambridge Biomedical Campus. Its product portfolio covers cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory illnesses. It has been among the largest pharmaceutical corporations in the world since the merger and has acquired a number of businesses, notably Cambridge Antibody Technology. In 2021, India authorized the use of the Oxford-AstraZeneca vaccine, opening the door for a widespread immunization campaign in the second-most populous nation in the world. It was revealed that the Oxford-AstraZeneca shot would be produced domestically by the Serum Institute of India (SII) under the trade name COVISHIELD.
The Bristol-Myers Squibb Company (BMS) is a pharmaceutical company with headquarters in the US. With its headquarters in New York City, one of the largest pharmaceutical companies in the world, BMS routinely makes the Fortune 500 list of the largest American companies. Cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders are among the therapeutic areas where Bristol Myers Squibb produces prescription medications and biologics. Lawrence, New Jersey, Summit, New Jersey, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain are the locations of BMS's main research and development facilities. Additional facilities can be found in Devens and Cambridge in Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, and Tokyo in Japan, India's Bangalore, and Wirral, United Kingdom. In the past, BMS operated an R&D facility in Wallingford, Connecticut. In June 2022, BMS announced that it would buy Turning Point Therapeutics Inc. for $4.1 billion in cash ($76 per share, a 122.5% premium to its most recent closing price), expanding its line-up of cancer medications to include repotrectinib.
Key Companies in the Hematuria Treatment market include
- AstraZeneca Plc
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Inc.
- Janssen Pharmaceuticals Inc.
- Merck & Co.
- Novartis International AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- The Medicines Company
Hematuria Treatment Industry Developments
April 2019:Otsuka Pharmaceutical Co., Ltd. declared that, JYNARQUE (tolvaptan) has been approved by the FDA as the first medication to be used to stop kidney function decline in persons at risk of autosomal dominant polycystic kidney disease increasing quickly.
April 2021:FDA-approved oral tablets of Farxiga (dapagliflozin) to lower the risk of renal function loss, kidney failure, cardiovascular death, and heart failure hospitalization in chronic renal disease patients who are at risk of disease progression.
June 2021:Eisai Co., Ltd. and Bristol-Myers Squibb Company have entered into an exclusive strategic collaboration agreement, in order to jointly develop and market MORAb-202, an antibody drug conjugate (ADC).
Hematuria Treatment Market Segmentation
Hematuria Treatment Type Outlook
Hematuria Treatment Causes Outlook
Hematuria Treatment Treatment Outlook
-
Drugs
-
Therapeutics
-
Others
Hematuria Treatment End-Users Outlook
-
Hospitals
-
Clinics
-
Laboratories
-
Research Centers
-
Others
Hematuria Treatment Regional Outlook
-
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size2022 |
USD 1.1 Billion |
| Market Size 2023 |
USD 1.13 Billion |
| Market Size2032 |
USD 1.40 Billion |
| Compound Annual Growth Rate (CAGR) |
2.70% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Causes, Treatment, End-Users, and Region |
| Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered |
The United States, Canada, Germany, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil |
| Key Companies Profiled |
 Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company, GlaxoSmithKline Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, and others. |
| Key Market Opportunities |
An increase in the amount of hematuria treatments supplied by neighborhood pharmacies |
| Key Market Dynamics |
Oral medications are anticipated to accelerate market expansion. |
Hematuria Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The size of the world market for hematuria treatment was estimated at USD 1.1 Billion in 2022.
The expected growth rate for the worldwide market is CAGR of 2.70% during the forecast period, 2023-2032.
The largest share belonged to Asia Pacific in the market
The main participants in the sector include are AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co.
The Microscopic Hematuria category dominated the market in 2022.
The Urinary Tract Infections (UTI) had the largest share in the market.
